Abstract

Blood-brain barrier (BBB) breakdown and immune cell infiltration into the central nervous system (CNS) are early hallmarks of multiple sclerosis (MS). High numbers of CD8+ T cells are found in MS lesions, and antigen (Ag) presentation at the BBB has been proposed to promote CD8+ T cell entry into the CNS. Here, we show that brain endothelial cells process and cross-present Ag, leading to effector CD8+ T cell differentiation. Under physiological flow in vitro, endothelial Ag presentation prevented CD8+ T cell crawling and diapedesis resulting in brain endothelial cell apoptosis and BBB breakdown. Brain endothelial Ag presentation in vivo was limited due to Ag uptake by CNS-resident macrophages but still reduced motility of Ag-specific CD8+ T cells within CNS microvessels. MHC class I-restricted Ag presentation at the BBB during neuroinflammation thus prohibits CD8+ T cell entry into the CNS and triggers CD8+ T cell-mediated focal BBB breakdown.

Blood-brain barrier (BBB) breakdown and immune cell infiltration into the central nervous system are early hallmarks of multiple sclerosis. Here, the authors demonstrate that brain endothelial cells cross-present antigen to CD8+ T cells, thereby preventing their migration and initiating BBB breakdown.

Details

Title
Antigen recognition detains CD8+ T cells at the blood-brain barrier and contributes to its breakdown
Author
Aydin, Sidar 1 ; Pareja, Javier 1 ; Schallenberg, Vivianne M. 1 ; Klopstein, Armelle 1 ; Gruber, Thomas 2   VIAFID ORCID Logo  ; Page, Nicolas 3   VIAFID ORCID Logo  ; Bouillet, Elisa 1   VIAFID ORCID Logo  ; Blanchard, Nicolas 4   VIAFID ORCID Logo  ; Liblau, Roland 4 ; Körbelin, Jakob 5   VIAFID ORCID Logo  ; Schwaninger, Markus 6   VIAFID ORCID Logo  ; Johnson, Aaron J. 7 ; Schenk, Mirjam 2   VIAFID ORCID Logo  ; Deutsch, Urban 1 ; Merkler, Doron 3   VIAFID ORCID Logo  ; Engelhardt, Britta 1   VIAFID ORCID Logo 

 University of Bern, Theodor Kocher Institute, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157) 
 University of Bern, Institute of Pathology, Experimental Pathology, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157) 
 University and University Hospitals of Geneva, Department of Pathology and Immunology, Division of Clinical Pathology, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
 University of Toulouse, CNRS, INSERM, UPS, Toulouse Institute for infectious and inflammatory diseases, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X) 
 University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and Bone Marrow Transplantation, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484) 
 University of Lübeck, Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672) 
 Mayo Clinic, Mayo Clinic Graduate School of Biomedical Sciences, College of Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
Pages
3106
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2820831697
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.